| dc.contributor.author | Reikvam, Håkon | en_US |
| dc.date.accessioned | 2012-03-19T10:44:58Z | |
| dc.date.available | 2012-03-19T10:44:58Z | |
| dc.date.issued | 2012-03-16 | eng |
| dc.identifier.isbn | 978-82-308-1979-1 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1956/5725 | |
| dc.language.iso | eng | eng |
| dc.publisher | The University of Bergen | eng |
| dc.relation.haspart | Paper I: Reikvam H., Hatfield K. J., Oyan A. M., Kalland K.H., Kittang A.O., Bruserud Ø. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology 84(3): 239-251, March 2010. Full text not available in BORA due to publisher restrictions. The article is available at: <a href="http://dx.doi.org/10.1111/j.1600-0609.2009.01382.x" target="blank"> http://dx.doi.org/10.1111/j.1600-0609.2009.01382.x</a> | en_US |
| dc.relation.haspart | Paper II: Reikvam H., Hatfield K. J., Lassalle P., Kittang A. O., Ersvaer E., Bruserud Ø. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs 19(2): 169-183, February 2010. Full text not available in BORA due to publisher restrictions. The article is available at: <a href="http://dx.doi.org/10.1517/13543780903485659" target="blank"> http://dx.doi.org/10.1517/13543780903485659</a> | en_US |
| dc.relation.haspart | Paper III: Reikvam H., Hatfield K. J., Ersvær E., Hovland R., Skavalnd J., Gjertsen B. T., Petersen K., Bruserud Ø. Heat shock proteins expression profile for AML patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology 156(4): 468-80, February 2012. Full text not available in BORA due to publisher restrictions. The article is available at: <a href="http://dx.doi.org/10.1111/j.1365-2141.2011.08960.x" target="blank"> http://dx.doi.org/10.1111/j.1365-2141.2011.08960.x</a> | en_US |
| dc.relation.haspart | Paper IV: Reikvam H., Hatfield K. J., Tamurini J., Poulain L., Ersvær E., Ryningen A., Bruserud Ø. Angiogenic signature for AML patients and the possible effects of different pharmacological agents acting on the PI3K-mTOR pathway. Full text not available in BORA. | en_US |
| dc.relation.haspart | Paper V: Reikvam H., Mosevoll K. A., Melve G., Günther C. C., Sjo M., Bentsen P. T., Bruserud Ø. The pretransplant serum cytokine profile in allogeneic stem cell recipients differ from healthy individuals and different profiles are associated with different risk of posttransplant complications. Biology of Blood and Marrow Transplantation 18(2): 190-9, February 2012. Full text not available in BORA due to publisher restrictions. The article is available at: <a href="http://dx.doi.org/10.1016/j.bbmt.2011.10.007" target="blank"> http://dx.doi.org/10.1016/j.bbmt.2011.10.007</a> | en_US |
| dc.title | New therapeutic targets in human acute myeloid leukemia | en_US |
| dc.type | Doctoral thesis | |
| dc.rights.holder | Copyright the author. All rights reserved | |
| dc.subject.nsi | VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Hematology: 775 | eng |
